In this issue:
Risankizumab vs. ustekinumab in moderate-to-severe CD
Continuing or stopping 5-ASAs when starting anti-TNFs for IBD
Onset of biologic/small molecule effects in moderately to severely active luminal CD
EEN vs. corticosteroids in children with CD
CD outcomes similar for delayed and early ustekinumab/adalimumab responders
Tofacitinib in acute severe UC
Seasonal variations of biomarkers in IBD
IBD prescribing in pregnancy, and congenital malformations
Early life/childhood environmental exposures influence IBD diagnosis age
Vedolizumab-adalimumab-methotrexate for CD
Please login below to download this issue (PDF)